Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. has renewed its distribution collaboration with Sinopharm, extending the agreement until December 2028. This renewal, subject to Hong Kong Listing Rules, positions Sinopharm as a key distributor of Henlius’s products, impacting the company’s market reach and operational strategy. The agreement’s renewal underscores the strategic importance of Sinopharm in Henlius’s distribution network and involves compliance with connected transaction regulations, necessitating shareholder approval and independent financial advice.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and distribution of biopharmaceutical products. The company is involved in producing and distributing a range of therapeutic products, with a market focus on leveraging partnerships for distribution, such as its collaboration with Sinopharm.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
See more data about 2696 stock on TipRanks’ Stock Analysis page.